BCDA - biocardia.com Sales Growth YoY (TTM)

Graphic logo of BioCardia Inc (BCDA)

BioCardia, Inc. (BCDA) management is focused on developing cell-based therapies for heart failure. The LTM sales growth YoY serves as a stability indicator, where the -100.00 mark reflects the latest data. Risks are linked to single-product dependency and financial pressure; however, patent protection for myocardial delivery systems and stringent FDA requirements create a significant moat for the business.

BCDA - BioCardia, Inc Sales Growth YoY (TTM) over the range 02/11/2024 - 11/15/2026

BioCardia Inc. (BCDA) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Market Chart BioCardia, Inc|BCDA - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization BioCardia, Inc|BCDA - Real Price to Acquire Entire Company
- book value of equity indicators:
Accounting Value of a Share BioCardia|BCDA - Book Capitalization|Market Capitalization to Book Value biocardia.com|BCDA - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio BioCardia, Inc.|BCDA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BioCardia, Inc|BCDA - Company Total Debt|Debts to Net Assets BioCardia, Inc.|BCDA - Company Long-Term Debts|Company Short-Term Debt BioCardia|Quick Liquidity Indicator biocardia.com
- earnings and market ratios statistics:
BCDA - Net Profit|Net Profit Forecast BioCardia, Inc.|BCDA - P/E Multiple|Forward P/E Multiple BioCardia, Inc.|BCDA - PEG Multiple|Business Value to Operating Income Before Depreciation BioCardia, Inc.|BCDA - Operating profit EBITDA|Net earnings per one share for the last twelve months BioCardia|BCDA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth biocardia.com|BCDA - Earnings per share growth in current year|Expected earnings per share trend next year BioCardia, Inc.
- sales revenue and business income indicators:
BCDA - Company Sales|Company Projected Revenue Volume BioCardia, Inc|BCDA - P/S Multiple|Price-to-Projected Revenue Ratio BioCardia, Inc.|BCDA - Sales Growth YoY (TTM)
Fundamental company valuation:BCDA BioCardia, Inc
Flagship merchandise of BioCardia

For BioCardia, Inc. (BCDA), a leader in intracardiac delivery of cell therapy, this indicator determines the scaling speed of the commercial success of innovative myocardial restoration systems. By analyzing the year-over-year (TTM) operating revenue dynamics on the GURU.Markets platform, an investor can observe the smoothed revenue growth rate over a rolling year, where extreme values signal either an expansion phase or the risk of an imminent slowdown in fundamental growth.

Who BioCardia, Inc. competes with

Regeneron Corp (REGN) - Trailing Twelve Months Revenue Growth|IRTC: Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) LNTH (Lantheus Holdings, Inc.)|MLYS (Mineralys Therapeutics, Inc.) - Revenue Growth YoY (Last 12 Months)|HeartFlow, Inc. - Revenue Dynamics YoY (Last Twelve Months)|KMTS (Kestra Medical Corp) - Sales Growth YoY (TTM)|ESPR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Amarin Corporation (AMRN)|Anteris - Sales Growth YoY (Last 12 Months)|Sales Growth YoY (Last Twelve Months) Tenaya TNYA|CVRX: Sales Growth YoY (Last 12 Months)|MIST - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth CRDL|BEAT: Sales Growth YoY (TTM)|TENX: Revenue Change YoY (Last 12 Months)|ADGM (Adagio Medical) - Sales Growth YoY (TTM)|Catheter Precision Inc (VTAK) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (TTM) ABIO|Revenue Change YoY (Last 12 Months) ACST|Aerovate - Revenue Growth YoY (Last 12 Months)|Annual Revenue Growth (Last Twelve Months) vervetx.com (VERV)|Windtree Therapeutics Inc. - Sales Growth YoY (TTM)